Abstract

Background:Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma.Patients and methods:Samples and clinical data from 238 patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics and survival.Results:Triple negative breast cancer group showed a high frequency among our cohort but we emphasize an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively).Conclusions:The classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated.

Highlights

  • Breast cancer (BC) represents the most common disease in the world (WHO, 2013)

  • The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma

  • When we analyzed the group of patients who didn’t receive endocrine therapy and focused on the impact of BCL2, we found that patients who expressed BCL2 have better survival than those who didn’t express BCL2 (p=0.021) (Figure 5-D)

Read more

Summary

Introduction

Breast cancer (BC) represents the most common disease in the world (WHO, 2013). It is the most frequent malignant neoplasm affecting Tunisian female patients with an incidence of 27.1/100,000 inhabitants (Maalej et al, 2004). The ER negative (ER-), PR negative (PR-), and HER2 negative (HER2-) tumors, known as triple-negative phenotype TNBC (ER-/PR-/HER2-) is characterized by expression of cytokeratin 5/6 (CK5/6) and/or the epidermal growth factor receptor (EGFR) (Nielsen et al, 2004 ; Change et al, 2008). For these patients, chemotherapy is the only available treatment. The goal from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival in young women patients with invasive ductal carcinoma. BCL2 should be clinically associated in current practice when young women specimens are diagnosticated

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call